Gu Jin’s team adds powerful evidence to neoadjuvant chemoradiotherapy prior to rectal cancer surgery

DEC . 14 2018
Peking University, Dec. 14, 2018: Professor Gu Jin’s team published a research article in Cancer Immunology Resarch one of the AACR publications, titled “Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy”.

The study pointed out that for rectal cancer, especially in the treatment of the locally advanced mid/low rectal cancer, chemoradiotherapy prior to the surgery could increase the chances of retaining the anus and the rate of local control. The researchers believed that neoadjuvant chemoradiotherapy (nCRT) activated somatic tumor specific immunity by inducing the tumor cell mutation and the increase of neoantigens, which made nCRT patients potential candidates for CPI therapy. In future research, they will study the tumor mutation burden and CD8 expression in order to stratify patients responding to chemo-and immunotherapy.  

Written by:
Lang Lang
Edited by: Huang Weijian
Source: PKU Shougang Hospital